Company Overview and News
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- First Majestic Silver Corp. ("First Majestic" or the "Company") (NYSE:AG) (TSX:FR) (Frankfurt:FMV) announces total production in the first quarter of 2018 from its six operating silver mines reached 3.9 million equivalent ounces of silver. Total production consisted of 2.2 million ounces of silver, 15,887 ounces of gold, 4.4 million pounds of lead and 1.
Usually, precious metals mining companies follow precious metals. When precious metals rose on April 11, 2018, miners followed suit. Most miners saw an up day on April 11, though that may not always be the case.
Recently, the unrest in the markets has had a big effect on precious metals and the US dollar. The US dollar has a big impact on dollar-denominated precious metals and also on mining companies. In this part of the series, we’ll look at miners’ RSI (relative strength index) scores and implied volatility. The miners we’ve selected for our analysis are First Majestic Silver (AG), B2Gold (BTG), Royal Gold (RGLD), and Goldcorp (GG).
When considering the performance of precious metals and precious metal mining companies, it’s important to analyze their interrelationship by way of ratios. There has been a significant up-and-down movement in the precious metals since the beginning of 2018. On a YTD (year-to-date) basis, gold has risen 1.4% and silver has fallen 4.3%. Silver has been weak compared to gold over the past few months.
VANCOUVER, British Columbia, April 05, 2018 (GLOBE NEWSWIRE) -- Evrim Resources Corp. (TSX.V:EVM) (“Evrim” or the “Company”) is pleased to announce that a maiden resource on the Ermitaño West vein that comprises part of the Ermitaño property was announced by earn-in partner First Majestic Silver Corp. (“First Majestic”) on March 29, 2018. Inferred resources of 40.8 million ounces silver equivalent have been calculated by First Majestic with an average grade of 4.
Over the last week, we saw some crucial economic numbers for the United States, including quarterly GDP, a measurement of the annualized change in the inflation-adjusted value of all goods and services over the last quarter. The market was expecting this number to be 2.7%. However, the outcome beat expectations at 2.9%. A better-than-expected number could be detrimental for gold since the demand for this safe-haven asset decreases.
The recent FOMC (Federal Open Market Committee) meeting was more dovish than expected, which gave more breathing room for precious metals. Investors were widely expecting at least three more rate hikes in 2018. However, now we’re expecting only two. Although interest rates were raised, the overall meeting seemed more dovish than expected.
Mining stocks tend to move in accordance with gold prices. In this final part of the series, we’ll analyze the correlation between gold and four mining stocks: First Majestic Silver (AG), B2Gold (BTG), Gold Fields (GFI), and Agnico-Eagle Mines (AEM). Among the miners under consideration, Gold Fields has the highest correlation with gold, while B2Gold has the lowest correlation.
On March 23, gold touched a two-week high and closed at $1,349.30 per ounce, and silver ended the day at $16.50 per ounce. The metals likely rose due to the US dollar falling. The US dollar, depicted by the DXY Currency Index (UUP), fell 0.42% on Friday and had fallen 0.83% in the last five days.
Mining shares tend to move with gold prices. For our correlation analysis, we’ll compare gold with four mining stocks: Alamos Gold (AGI), First Majestic Silver (AG), B2Gold (BTG), and Royal Gold (RGLD). Mining funds also have high correlations with gold.
Out of all the silver miners (SIL) under discussion in this series, Hecla Mining (HL) has among the fewest “buy” ratings, with only 45% of analysts recommending its stock—just above Tahoe Resources’ (TAHO) 43% “buy” ratings.
Year-to-date (or YTD), silver has underperformed gold. As of March 16, 2018, the SPDR Gold Shares ETF (GLD), which tracks gold prices, had risen 0.8% YTD. During the same period, the iShares Silver Trust ETF (SLV), which tracks silver prices, had fallen 3.8%.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...